Investment in Cubist (CBST) has now become a twofold offer. If the company defends its patent position against Teva Pharmaceutical Industries Ltd (TEVA) who produces the low-cost generic version of the drug Cubicin, shares will surge. If Teva wins the fight, Cubist is likely a penny stock.

Within the first few months of 2008, shares of a billion-dollar biotech ran back and forth between $20 and $30… losing 50% one week only to pick it back up the next.